Thoracic oncology and neuroendocrine neoplasms
Clinical research at Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz includes treatment strategies for small cell lung cancer, non-small cell lung cancer with EGFR alterations, and advanced neuroendocrine neoplasias G3.
- Immunotherapy in lung cancer
- Targeted therapy for EGFR-mutated disease
- Advanced neuroendocrine tumor management
The sponsor’s trial portfolio in this area also covers combinations of systemic and local treatments for disease control and progression management.
Gastrointestinal oncology
Research activity extends to locally advanced rectal cancer, with interest in treatment intensification and organ-preserving approaches in colorectal cancer.
- Total neoadjuvant therapy
- Rectal cancer response assessment
- Immune-based therapy in gastrointestinal malignancy
This area reflects a focus on improving local disease control and long-term oncologic outcomes in advanced rectal cancer.
Haematological malignancies
The sponsor supports studies in aggressive and relapsed lymphoid cancers, including malignant B-cell lymphoma and mantle cell lymphoma.
- B-cell lymphoma treatment combinations
- Anti-CD20-based regimens
- Novel targeted agents in lymphoma
These trials address both disease control and treatment selection in hematologic oncology.
Orthopaedic surgery and perioperative thromboprophylaxis
Clinical research also includes elective unilateral primary hip arthroplasty with a fast-track protocol, focusing on postoperative recovery and prevention of venous thromboembolism.
- Hip arthroplasty recovery pathways
- Direct oral anticoagulants
- Postoperative VTE prevention
The sponsor’s work in this field connects enhanced recovery care with surgical safety and anticoagulation management.
Neurology and stroke care
Another therapeutic area is stroke, indicating involvement in acute and secondary prevention research within cerebrovascular disease.
- Stroke treatment research
- Cerebrovascular outcomes
- Neurological recovery
This adds a non-oncologic dimension to the sponsor’s clinical research portfolio.
